Sean Brynjelsen, President and CEO of Eton Pharmaceuticals, Inc. (NASDAQ:ETON), filed a Form 4 on August 20, 2026, disclosing four open-market sales of common stock that occurred on August 19 and August 20, 2026.

Key Highlights

  • Four separate dispositions: Brynjelsen disposed of shares across four transactions spanning two trading days, August 19 and August 20, 2026.
  • August 19 sale: 8,978 shares sold at a weighted average price of $62.65, with individual trade prices ranging from $62.50 to $63.41.
  • First August 20 sale: 47,307 shares sold at a weighted average price of $60.17, with individual trade prices ranging from $59.59 to $60.59.
  • Second August 20 sale: 36,373 shares sold at a weighted average price of $61.11, with individual trade prices ranging from $60.61 to $61.61.
  • Third August 20 sale: 7,342 shares sold at a weighted average price of $62.12, with individual trade prices ranging from $61.63 to $62.52.
  • Remaining ownership: Following all reported transactions, Brynjelsen directly holds 961,194 shares of common stock, according to the filing.

Transaction Details and Ownership Changes for Eton Pharmaceuticals' President and CEO

According to the filing, Sean Brynjelsen, who serves as both a Director and President and CEO of Eton Pharmaceuticals, Inc., reported all transactions as direct dispositions of common stock, each coded "S" for open-market sale. The filing was submitted by one reporting person and is not an amendment to a prior filing. The earliest transaction date listed is August 19, 2026.

The filing notes that each weighted average price reflects sales executed across multiple individual trades within specified price ranges. Per the explanation of responses included in the filing, Brynjelsen will provide full information on the number of shares sold at each separate price to the Securities and Exchange Commission staff, the issuer, or a security holder upon request. Prior to the first reported transaction, Brynjelsen held 1,061,194 shares, and the successive dispositions reduced that position to 961,194 shares directly held after the final August 20 sale.

Eton Pharmaceuticals, Inc. is listed on NASDAQ under the symbol ETON, and its address on file for the reporting person is 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208. No derivative securities were reported as acquired or disposed of in this filing, and Table II contains no entries.

What Was Disclosed

The filing discloses four open-market sales of Eton Pharmaceuticals common stock by President and CEO Sean Brynjelsen on August 19 and August 20, 2026, at weighted average prices between $60.17 and $62.65, leaving him with a direct beneficial ownership of 961,194 shares.